- Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
- Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Announces Updates on its PCSK9 Program
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
- Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
- Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.41 |
---|---|
High | 5.43 |
Low | 5.23 |
Bid | 5.28 |
Offer | 5.30 |
Previous close | 5.33 |
Average volume | 1.61m |
---|---|
Shares outstanding | 83.97m |
Free float | 77.50m |
P/E (TTM) | -- |
Market cap | 443.34m USD |
EPS (TTM) | -2.87 USD |
Data delayed at least 15 minutes, as of May 24 2024 21:00 BST.
More ▼